Connect with us
  • Elysium

Brain injury news

Can the eye hold the key to brain injury detection?

New diagnostic test developed which can determine biomarkers through shining a laser into a person’s eye



A novel diagnostic device has been developed to detect traumatic brain injury (TBI) by shining a laser into the eye. 

The technique is dramatically different from other diagnostic methods and is expected to be developed into a hand-held device for use in the critical ‘golden hour’ after traumatic brain injury, when life critical decisions on treatment must be made.

It works by scanning the back of the eye where the optic nerve sits. Because the optic nerve is so closely linked to the brain, it carries the same biological information in the form of protein and lipid biomarkers. 

These biomarkers exist in a very tightly regulated balance, meaning even the slightest change may have serious effects on the ‘brain-health’. TBI causes these biomarkers to change, indicating that something is wrong.

The device incorporates a class 1, CE marked, eye-safe laser and a unique Raman spectroscopy system, which uses light to reveal the biochemical and structural properties of molecules by detecting how they scatter light, to detect the presence and levels of known biomarkers for brain injury.

The study and creation, by researchers at the University of Birmingham, helps to answer an urgent need for quicker and more efficient diagnostics for TBI. 

Led by Professor Pola Goldberg Oppenheimer, the team designed and developed the novel diagnostic hand-held device to assess patients as soon as injury occurs. 

It is fast, precise and non-invasive for the patient, causing no additional discomfort, can provide information on the severity of the trauma, and will be suitable to be used on-site – at the roadside, on the battlefield or on the sports pitch – to assess TBI.

Prof Oppenheimer said: “Early diagnosis of TBI is crucial, as life-critical decisions on treatment must be made with the first ‘golden hour’ after injury.  

“However current diagnostic procedure relies on observation by ambulance crews, and MRI or CT scans at a hospital – which may be some distance away.”

Previous research has demonstrated the technology can accurately detect the changes in animal brain and eye tissues with different levels of brain injuries – picking up the slightest changes.

The device which has been developed detects and analyses the composition and balance of these biomarkers to create ‘molecular fingerprints’. 

The study details the development, manufacture, and optimisation of a proof-of-concept prototype, and its use in reading biochemical fingerprints of brain injury on the optic nerve, to see whether it is a viable and effective approach for initial ‘on the scene’ diagnosis of TBI.

The researchers constructed a phantom eye to test its alignment and ability to focus on the back of the eye, used animal tissue to test whether it could discern between TBI and non-TBI states, and also developed decision support tools for the device, using AI, to rapidly classify TBIs.

The device is now ready for further evaluation including clinical feasibility and efficacy studies, and patient acceptability.

The researchers expect the diagnostic device to be developed into a portable technology which is suitable for use in point-of-care conditions capable to rapidly determine whether TBI occurs as well as classify whether it is mild, moderate or severe, and therefore, direct triage appropriately and in timely manner.